PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 11.76M 10.22M 9.53M 8.77M 16.52M 1.12B 16.8M 112M 44.06M 559M 44.16M 43.19M 1.85B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 16.68M 14.49M 13.51M 12.44M 23.43M 1.59B 23.83M 160M 62.49M 793M 62.64M 61.25M 2.63B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	352,666.67
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-88.11%	11.69M
VERACYTE, INC.	-3.17%	-20.77%	+89.72%	+73.50%	3.72B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.39%	+3.77%	+123.72%	+190.33%	3.59B
CAREDX, INC.	+9.47%	+28.84%	+291.57%	+324.96%	2.26B
BGI GENOMICS CO., LTD.	-0.42%	+4.11%	-27.65%	-35.55%	2.17B
IOVANCE BIOTHERAPEUTICS, INC.	+6.02%	-13.53%	+61.01%	-39.90%	1.82B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.28%	-5.03%	+189.19%	-46.28%	969M
SEEGENE, INC.	-0.74%	-2.55%	-8.09%	+20.27%	853M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.46%	+7.96%	-37.98%	-10.07%	511M
CURIOX BIOSYSTEMS CO., LTD	+2.80%	-0.52%	+2.52%	-	449M
Average	+0.79%	-1.44%	+68.40%	+43.24%	1.64B
Weighted average by Cap.	+1.00%	-3.01%	+100.68%	+94.84%

	2023	2024
Net sales	8.43B 5.9M 5.13M 4.78M 4.4M 8.29M 562M 8.43M 56.43M 22.1M 280M 22.15M 21.66M 931M	1.25B 872K 758K 707K 651K 1.22M 83.14M 1.25M 8.34M 3.27M 41.45M 3.27M 3.2M 138M
Net income	-20.32B -14.22M -12.35M -11.52M -10.61M -19.97M -1.36B -20.32M -136M -53.27M -676M -53.4M -52.22M -2.24B	-52.34B -36.64M -31.82M -29.68M -27.32M -51.45M -3.49B -52.34M -350M -137M -1.74B -138M -135M -5.78B
Net Debt	7.2B 5.04M 4.38M 4.08M 3.76M 7.08M 481M 7.2M 48.22M 18.89M 240M 18.93M 18.51M 795M	7.03B 4.92M 4.27M 3.99M 3.67M 6.91M 469M 7.03M 47.06M 18.43M 234M 18.48M 18.07M 776M